Spring Bank Pharmaceuticals, Inc. (SBPH): Price and Financial Metrics
GET POWR RATINGS... FREE!
SBPH Stock Price Chart Interactive Chart >
SBPH Price/Volume Stats
|Current price||$1.21||52-week high||$4.80|
|Prev. close||$1.21||52-week low||$0.80|
|Day high||$1.30||Avg. volume||177,606|
|50-day MA||$1.30||Dividend yield||N/A|
|200-day MA||$1.37||Market Cap||20.89M|
Spring Bank Pharmaceuticals, Inc. (SBPH) Company Bio
Spring Bank Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of a class of therapeutics using its proprietary small molecule nucleic acid hybrid (SMNH) chemistry platform. The company was founded in 2002 and is based in Milford, Massachusetts
SBPH Latest News Stream
|Loading, please wait...|
SBPH Latest Social Stream
View Full SBPH Social Stream
Latest SBPH News From Around the Web
Below are the latest news stories about Spring Bank Pharmaceuticals Inc that investors may wish to consider to help them evaluate SBPH as an investment opportunity.
NEW YORK, Sept. 22, 2020 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Spring Bank Pharmaceuticals, Inc. ("SBPH" or the "Company") (NASDAQ: SBPH) in connection with SBPH's July 29, 2020 merger and…
ALERT: Halper Sadeh LLP Is Investigating the Following Mergers; Shareholders are Encouraged to Contact the Firm - SBPH, VAR, JCAP, GLIBA
NEW YORK, Sept. 3, 2020 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating: Spring Bank Pharmaceuticals, Inc. (NASDAQ: SBPH) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its…
The combined company will be headquartered at Babraham Research Campus and in Cambridge, Massachusetts.
Rowley Law PLLC is investigating potential securities law violations by Spring Bank Pharmaceuticals, Inc. (NASDAQ: SBPH) and its board of directors concerning the proposed merger of the company with F-star Therapeutics, Limited. Spring Bank Pharmaceuticals stockholders will own approximately 38.8% of the combined company. The transaction is expected to close in late 2020.
In a reverse merger aimed at a Nasdaq listing, privately held F-star Therapeutics will combine with Spring Bank Pharmaceuticals ([[SBPH]] -10.1%). The new organization will do business under the F-star monikerCurrent Spring Bank and F-star equity holders will own ~38.8% and 61.2%, respectively, of the combined company.The new firm will focus...
SBPH Price Returns